Sight Sciences executive plans $90K stock sale

Alison Bauerlein files Form 144 to sell 25,874 SGHT shares

Apr. 2, 2026 at 8:57pm

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up of intricate financial machinery, such as gears, levers, and computer components, conveying the scale and power of the financial system.An insider stock sale by a Sight Sciences executive highlights the complex machinery behind corporate finance.Menlo Park Today

Alison Bauerlein, an executive at Sight Sciences, Inc. (SGHT), has filed a Form 144 with the SEC indicating her intention to sell 25,874 shares of the company's common stock. The proposed sale, valued at around $90,000, comes just a few months after Bauerlein sold 20,543 shares in January.

Why it matters

Insider stock sales can provide insight into an executive's confidence in a company's future performance. While not necessarily indicative of any broader issues, large sales by key personnel are often closely watched by investors and analysts.

The details

According to the filing, Bauerlein acquired the 25,874 shares through restricted stock vesting as part of her compensation. The shares are proposed to be sold through Fidelity Brokerage Services. Bauerlein's previous sales in January totaled 20,543 shares.

  • Bauerlein acquired the 25,874 shares on March 31, 2026 through restricted stock vesting.
  • The proposed sale is set to occur on April 2, 2026.

The players

Alison Bauerlein

An executive at Sight Sciences, Inc. (SGHT) who is proposing to sell 25,874 shares of the company's common stock.

Sight Sciences, Inc.

A medical technology company that develops and commercializes ophthalmic and optometric products and procedures designed to treat eye diseases and conditions.

Got photos? Submit your photos here. ›

The takeaway

While insider stock sales can raise questions, it's important to consider the full context. Bauerlein's proposed sale appears to be part of her regular compensation and portfolio management, rather than a sign of broader concerns. Investors will likely continue to monitor Sight Sciences' performance and any future insider transactions.